The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine for advanced endometrial carcinoma (EMC): A review of the MSKCC experience.
R. N. Grisham
No relevant relationships to disclose
C. H. Adaniel
No relevant relationships to disclose
D. M. Hyman
No relevant relationships to disclose
W. Ma
No relevant relationships to disclose
A. Iasonos
No relevant relationships to disclose
C. Aghajanian
No relevant relationships to disclose
J. A. Konner
No relevant relationships to disclose